Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response. - Erkizia-Santamaría I; Alles-Pascual R; Horrillo I; Meana JJ; Ortega JE. (Biomedicine & Pharmacotherapy, 2022)

Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives. - Kaypak AC; Raz A. (2022)

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. - Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA. (2022)

Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying. - Sweeney MM; Nayak S; Hurwitz ES; Mitchell LN; Swift TC; Griffiths RR. (PLoS ONE, 2022)

Skepticism about Recent Evidence That Psilocybin "Liberates" Depressed Minds. - Doss MK; Barrett FS; Corlett PR. (ACS Chemical Neuroscience, 2022)

Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism. - Pilc A; Machaczka A; Kawalec P; Smith JL; Witkin JM. (Expert Opinion on Drug Discovery, 2022)

Examining Attitudes to Psilocybin: Should Candidates for Medical Psilocybin be Required to Pass a Contextual Suitability Test? - Mark Molumby; Keith Gaynor; Suzanne Guérin; Róisín McNamara (Journal of Humanistic Psychology, 2022)

Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in Gymnopilus dilepis Mushroom via Amino Acid Metabolism Pathways. - Yao S; Wei C; Lin H; Zhang P; Liu Y; Deng Y; Huang Q; Xie B. (Journal of Fungi, 2022)

Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling. - Henningfield JE; Coe MA; Griffiths RR; Belouin SJ; Berger A; Coker AR; Comer SD; Heal DJ; Hendricks PS; Nichols CD; Sapienza F; Vocci FJ; et al. (2022)

The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. - Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; et al. (2022)

Insights for Modern Applications of Psilocybin Therapy from a Case Study of Traditional Mazatec Medicine - Jesús M. González Mariscal; Paulina E. Sosa-Cortés (Anthropology of Consciousness, 2022)

Psilocybin and the Meaning Response: Exploring the Healing Process in a Retreat Setting in Jamaica - María de Ángeles Equihua Orozco; Shana Harris (Anthropology of Consciousness, 2022)

Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines. - Belouin SJ; Averill LA; Henningfield JE; Xenakis SN; Donato I; Grob CS; Berger A; Magar V; Danforth AL; Anderson BT. (2022)

Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review. - Prouzeau D; Conejero I; Voyvodic PL; Becamel C; Abbar M; Lopez-Castroman J. (2022)

Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice. - Fadahunsi N; Lund J; Breum AW; Mathiesen CV; Larsen IB; Knudsen GM; Klein AB; Clemmensen C. (Translational Psychiatry, 2022)

Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States. - Levin A; Nagib PB; Deiparine S; Gao T; Mitchell J; Davis AK. (2022)

Prophylactic Effects of Psilocybin on Chronic Cluster Headache: an Open-label Clinical Trial and Neuroimaging Study - Gitte Moos Knudsen (ClinicalTrials.gov, 2022)

Differences across sexes on head-twitch behavior and 5-HT2A receptor signaling in C57BL/6J mice. - Jaster AM; Younkin J; Cuddy T; de la Fuente Revenga M; Poklis JL; Dozmorov MG; González-Maeso J. (2022)

Experiences With Sacred Mushrooms and Psilocybin In Dialogue: Transdisciplinary Interpretations Of The “Velada” - Antonella Fagetti; Roberto E. Mercadillo (Anthropology of Consciousness, 2022)

The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world. - Watts R; Kettner H; Geerts D; Gandy S; Kartner L; Mertens L; Timmermann C; Nour MM; Kaelen M; Nutt D; Carhart-Harris R; Roseman L. (Psychopharmacology, 2022)

Psilocybin use patterns and perception of risk among a cohort of Black individuals with Opioid Use Disorder. - Clifton JM; Belcher AM; Greenblatt AD; Welsh CM; Cole TO; Davis AK. (Journal of Psychedelic Studies, 2022)

Psilocybin administration - George Winter (Journal of Prescribing Practice, 2022)

Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. - Cavanna F; Muller S; de la Fuente LA; Zamberlan F; Palmucci M; Janeckova L; Kuchar M; Pallavicini C; Tagliazucchi E. (Translational Psychiatry, 2022)

Depression: Psilocybin etwas besser als Escitalopram (Zeitschrift für Phytotherapie, 2022)

Med Check: Psilocybin for OCD, Nuplazid Vote, and More - Terri D’Arrigo (Psychiatric News, 2022)

Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness. - Rosa WE; Sager Z; Miller M; Bernstein I; Doerner Rinaldi A; Addicott K; Ljuslin M; Adrian C; Back AL; Beachy J; Bossis AP; Breitbart WS; et al. (Journal of palliative medicine, 2022)

The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field. - Polito V; Liknaitzky P (Neuroscience and biobehavioral reviews, 2022)

From Mushrooms to Myolysis: A Case of Rhabdo in Psilocybin-Induced Mood and Psychotic Disorder. - Suleiman M; Basu A; Belal S; Jacob T. (The Journal of Nervous and Mental Disease, 2022)

Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample. - Nygart VA; Pommerencke LM; Haijen E; Kettner H; Kaelen M; Mortensen EL; Nutt DJ; Carhart-Harris RL; Erritzoe D (Journal of psychopharmacology (Oxford, England), 2022)

Mushrooms' Legal Trip: As psilocybin research ramps up, the drug's status under the law is shifting. - Makin S. (2022)

Molecular insights into the regulation of constitutive activity by RNA editing of 5HT2C serotonin receptors. - Gumpper RH; Fay JF; Roth BL. (2022)

Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples - James A. Kaduk; Alexander M. Sherwood; Robert B. Kargbo; Kristi W. Kaylo; Poncho Meisenheimer; Nicholas V. Cozzi (Acta Crystallographica Section A Foundations and Advances, 2022)

Author Correction: Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls. - Rootman JM; Kiraga M; Kryskow P; Harvey K; Stamets P; Santos-Brault E; Kuypers KPC; Walsh Z. (2022)

Psilocybin reduces low frequency oscillatory power and neuronal phase-locking in the anterior cingulate cortex of awake rodents. - Golden CT; Chadderton P. (Scientific Reports, 2022)

Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy - University of California; San Diego (ClinicalTrials.gov, 2022)

Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 receptors in the head twitch response induced by 5-hydroxytryptophan and psilocybin: Translational implications - Shahar O; Botvinnik A; Esh-Zuntz N; Brownstien M; Wolf R; Wolf G; Lerer B; Lifschytz T. (bioRxiv, 2022)

9 Signs You Need Help With Magic Mushrooms uk - y7fceaj128 (Zenodo (CERN European Organization for Nuclear Research), 2022)

Magic Mushrooms - an exploratory look at how mental health professionals feel and think about Psilocybin. - Meyer TD; Meir P; Lex C; Soares JC. (Psychiatry Research, 2022)

Effect of psilocybin on marble-burying in ICR mice: Role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder - Singh S; Botvinnik A; Shahar O; Wolf G; Yakobi C; Saban M; Salama A; Lotan A; Lerer B; Lifschytz T. (bioRxiv, 2022)

Mapping Pharmacologically-induced Functional Reorganisation onto the Brain’s Neurotransmitter Landscape - Luppi AI; Hansen JY; Adapa R; Carhart-Harris RL; Roseman L; Timmermann C; Golkowski D; Golkowski D; Ranft A; Ilg R; Jordan D; Bonhomme V; et al. (bioRxiv, 2022)

Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review. - Ko K; Knight G; Rucker JJ; Cleare AJ. (2022)

Rapid-Response Treatments for Depression and Requests for Physician-Assisted Death: An Ethical Analysis. - Berens N; Kim SY. (2022)

Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy. - Dodd S; Norman TR; Eyre HA; Stahl SM; Phillips A; Carvalho AF; Berk M. (2022)

Psilocybin-induced reduction in chronic cluster headache attack frequency correlates with changes in hypothalamic functional connectivity - Madsen MK; Petersen AS; Stenbæk DS; Sørensen IM; Schiønning H; Fjeld T; Nykjær CH; Ulv Larsen SM; Grzywacz M; Mathiesen T; Klausen IL; Overgaard-Hansen O; et al. (medRxiv, 2022)

From Relaxed Beliefs Under Psychedelics (REBUS) to Revised Beliefs After Psychedelics (REBAS): Preliminary Development of the RElaxed Beliefs Questionnaire (REB-Q) - Zeifman R; Spriggs MJ; Kettner H; Lyons T; Rosas F; Mediano P; Erritzoe D; Carhart-Harris R. (PsyArXiv, 2022)

From Relaxed Beliefs Under Psychedelics (REBUS) to Revised Beliefs After Psychedelics (REBAS): Preliminary Development of the RElaxed Beliefs Questionnaire (REB-Q) (PsyArXiv, 2022)

Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees. - Kiraga MK; Kuypers KPC; Uthaug MV; Ramaekers JG; Mason NL. (Frontiers in Psychiatry, 2022)

Pharmacotherapy for the Secondary Prevention of Suicide: Leads from the Social Pain Hypothesis - Rajkumar RP. (Preprints.org, 2022)

Psychedelics in the treatment of unipolar and bipolar depression. - Bosch OG; Halm S; Seifritz E. (2022)

Synthesis, Structural Characterization, and Pharmacological Activity of Novel Quaternary Salts of 4-Substituted Tryptamines. - Glatfelter GC; Pham DNK; Walther D; Golen JA; Chadeayne AR; Baumann MH; Manke DR. (ACS Omega, 2022)

Psychedelic drugs for psychiatric disorders. - da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M. (2022)

Brain dynamics predictive of response to psilocybin for treatment-resistant depression - Vohryzek J; Cabral J; Lord L; Fernandes HM; Roseman L; Nutt DJ; Carhart-Harris RL; Deco G; Kringelbach ML. (bioRxiv, 2022)

Synapses, predictions, and prediction errors: a neocortical computational study of MDD using the temporal memory algorithm of HTM - Sherif MA; Khalil MZ; Shukla R; Brown JC; Carpenter LL. (bioRxiv, 2022)

Electrical spiking of psilocybin fungi - Gandia A; Adamatzky A. (bioRxiv, 2022)

Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity. - Gaddis A; Lidstone DE; Nebel MB; Griffiths RR; Mostofsky SH; Mejia AF; Barrett FS. (NeuroImage, 2022)

Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses. - McCulloch DE; Knudsen GM; Barrett FS; Doss MK; Carhart-Harris RL; Rosas FE; Deco G; Kringelbach ML; Preller KH; Ramaekers JG; Mason NL; Müller F; et al. (Neuroscience and biobehavioral reviews, 2022)

A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression - Nayak SM; Bari BA; Yaden DB; Spriggs MJ; Rosas F; Peill JM; Giribaldi B; Erritzoe D; Nutt D; Carhart-Harris R. (PsyArXiv, 2022)

Psychedelic-inspired approaches for treating neurodegenerative disorders. - Saeger HN; Olson DE (Journal of neurochemistry, 2022)

Classic Psychedelics and Human-Animal Relations. - Pöllänen E; Osika W; Stenfors CUD; Simonsson O (International journal of environmental research and public health, 2022)

Self-administration of Psilocybin in the Setting of Treatment-resistant Depression. - Lyons A. (PubMed, 2022)

A Single Method for 127 Recommended and Additional DUID Drugs in Blood and Urine by LC-MS-MS. - Farley M; Tran H; Towler S; Gevorkyan J; Pearring S; Rodda LN. (2022)

A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression (PsyArXiv, 2022)

Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls - Joseph M. Rootman; Maggie Kiraga; Pamela Kryskow; Kalin Harvey; Paul Stamets; Eesmyal Santos-Brault; Kim P.C. Kuypers; Zach Walsh (VIUspace, 2022)

Randomized Double Blind Placebo Controlled Assessing the Efficacy of Micro-dosed Psilocybin in Reducing Anxiety and or Depression Levels in Adults - Wake Network; Inc. (ClinicalTrials.gov, 2022)

Neuroimaging in psychedelic drug development: Past, present, and future - Wall M; Harding R; Zafar R; Rabiner EA; Nutt D; Erritzoe D. (PsyArXiv, 2022)

Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls. - Rootman JM; Kiraga M; Kryskow P; Harvey K; Stamets P; Santos-Brault E; Kuypers KPC; Walsh Z. (Scientific Reports, 2022)

Neuroimaging in psychedelic drug development: Past, present, and future (PsyArXiv, 2022)

Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders. - Vorobyeva N; Kozlova AA. (2022)

3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Therapy in Hawaii: A Brief Review. - Inouye A; Wolfgang A. (2022)

Bacillus subtilis Produces Amino Acids to Stimulate Protein Synthesis in Ruminal Tissue Explants via the Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta-Serine/Threonine Kinase-Mammalian Target of Rapamycin Complex 1 Pathway. - Wang Q; Ren Y; Cui Y; Gao B; Zhang H; Jiang Q; Loor JJ; Deng Z; Xu C. (Frontiers in Veterinary Science, 2022)

Self-Reported Efficacy of Treatments in Cluster Headache: a Systematic Review of Survey Studies. - Rusanen SS; De S; Schindler EAD; Artto VA; Storvik M. (2022)

Associations between classic psychedelics and nicotine dependence in a nationally representative sample. - Jones G; Lipson J; Nock MK. (Scientific Reports, 2022)

Sustained effects of single doses of classical psychedelics in humans. - Knudsen GM. (2022)

[Attitudes of Mental Health Experts Towards Psilocybin]. - Schmidt C; Wolff M; Gründer G; Jungaberle H. (Fortschritte der Neurologie · Psychiatrie, 2022)

Psilocybin-Mediated Attenuation of Gamma Band Auditory Steady-State Responses (ASSR) Is Driven by the Intensity of Cognitive and Emotional Domains of Psychedelic Experience. - Viktorin V; Griškova-Bulanova I; Voicikas A; Dojčánová D; Zach P; Bravermanová A; Andrashko V; Tylš F; Korčák J; Viktorinová M; Koudelka V; Hájková K; et al. (Journal of Personalized Medicine, 2022)

Effect of Psilocybin and Ketamine on Brain Neurotransmitters, Glutamate Receptors, DNA and Rat Behavior. - Wojtas A; Bysiek A; Wawrzczak-Bargiela A; Szych Z; Majcher-Maślanka I; Herian M; Maćkowiak M; Gołembiowska K. (International Journal of Molecular Sciences, 2022)

Psychedelics as preventive treatment in headache and chronic pain disorders. - Schindler EAD. (2022)

Validation of the forced swim test in Drosophila, and its use to demonstrate psilocybin has long-lasting antidepressant-like effects in flies. - Hibicke M; Nichols CD. (Scientific Reports, 2022)

Genetic Survey of Psilocybe Natural Products. - Dörner S; Rogge K; Fricke J; Schäfer T; Wurlitzer JM; Gressler M; Pham DNK; Manke DR; Chadeayne AR; Hoffmeister D. (ChemBioChem, 2022)

Natural language signatures of psilocybin microdosing. - Sanz C; Cavanna F; Muller S; de la Fuente L; Zamberlan F; Palmucci M; Janeckova L; Kuchar M; Carrillo F; García AM; Pallavicini C; Tagliazucchi E. (Psychopharmacology, 2022)

Don't be afraid, try to meditate- potential effects on neural activity and connectivity of psilocybin-assisted mindfulness-based intervention for social anxiety disorder: A systematic review. - Felsch CL; Kuypers KPC. (2022)

Optimization through a Box-Behnken Experimental Design of the Microwave-Assisted Extraction of the Psychoactive Compounds in Hallucinogenic Fungi (Psylocibe cubensis). - Polo-Castellano C; Álvarez JÁ; Palma M; Barbero GF; Ayuso J; Ferreiro-González M. (Journal of Fungi, 2022)

Phosphate moiety in FDA-approved pharmaceutical salts and prodrugs. - Fulmali A; Bharate SS. (2022)

Neuropharmacological analysis of the anti-addictive and therapeutic effects of psilocybin - Anthony Principe (SURG Journal, 2022)

The safety and efficacy of psilocybin therapy in patients with cancer and major depressive disorder. - Manish Agrawal; Paul Thambi; Sarah Shnayder (Journal of Clinical Oncology, 2022)

Association of Psilocybin Use in Adolescents with Major Depressive Episode - Kaushal Shah; C. Trivedi; D. Kamrai; M. Akbar; W. Tankersley (European Psychiatry, 2022)

Serotonin toxicity of serotonergic psychedelics. - Malcolm B; Thomas K (Psychopharmacology, 2022)

Sex-specific effects of psychedelics on prepulse inhibition of startle in 129S6/SvEv mice. - Vohra HZ; Saunders JM; Jaster AM; de la Fuente Revenga M; Jimenez J; Fernández-Teruel A; Wolstenholme JT; Beardsley PM; González-Maeso J (Psychopharmacology, 2022)

How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework. - van den Berg M; Magaraggia I; Schreiber R; Hillhouse TM; Porter JH (Psychopharmacology, 2022)

Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits? - Husain MI; Umer M; Mulsant BH (Expert opinion on drug safety, 2022)

Neural mechanisms underlying psilocybin's therapeutic potential - the need for preclinical in vivo electrophysiology. - Smausz R; Neill J; Gigg J. (2022)

Postpartum depression: A role for psychedelics? - Jairaj C; Rucker JJ. (2022)

Review of potential psychedelic treatments for PTSD. - Henner RL; Keshavan MS; Hill KP. (2022)

Spatiotemporal Mapping of Online Interest in Cannabis and Popular Psychedelics before and during the COVID-19 Pandemic in Poland. - Al-Imam A; Motyka MA; Witulska Z; Younus M; Michalak M. (International Journal of Environmental Research and Public Health, 2022)

Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD. - Brandt SD; Kavanagh PV; Westphal F; Pulver B; Schwelm HM; Whitelock K; Stratford A; Auwärter V; Halberstadt AL. (Drug Testing and Analysis, 2022)

Unraveling the Mysteries of Mental Illness With Psilocybin. - Sotille R; Singh H; Weisman A; Vida T. (2022)

Unique Effects of Sedatives, Dissociatives, Psychedelics, Stimulants, and Cannabinoids on Episodic Memory: A Review and Reanalysis of Acute Drug Effects on Recollection, Familiarity, and Metamemory - Doss MK; Samaha J; Barrett FS; Griffiths RR; de Wit H; Gallo DA; Koen JD. (bioRxiv, 2022)

Psilocybin-Assisted Therapy Found to Improve Depression, Offer Other Benefits - Richard Karel (Psychiatric News, 2022)

An Overview on the Taxonomy, Phylogenetics and Ecology of the Psychedelic Genera Psilocybe, Panaeolus, Pluteus and Gymnopilus - Dominique Strauss; Soumya Ghosh; Zurika Murray; Marieka Gryzenhout (Frontiers in Forests and Global Change, 2022)

New Paradigms of Old Psychedelics in Schizophrenia. - Mahmood D; Alenezi SK; Anwar MJ; Azam F; Qureshi KA; Jaremko M. (2022)

Psychoactive Drugs in the Management of Post Traumatic Stress Disorder: A Promising New Horizon. - Elsouri KN; Kalhori S; Colunge D; Grabarczyk G; Hanna G; Carrasco C; Aleman Espino A; Francisco A; Borosky B; Bekheit B; Ighanifard M; Astudillo AA; et al. (2022)

Psilocybin Versus Ketamine - Fast Acting Antidepressant Strategies in Treatment-resistant Depression - National Institute of Mental Health; Czech Republic (ClinicalTrials.gov, 2022)

Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence. - Edinoff AN; Fort JM; Singh C; Wagner SE; Rodriguez JR; Johnson CA; Cornett EM; Murnane KS; Kaye AM; Kaye AD. (2022)

Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity. - Huang J; Pham M; Panenka WJ; Honer WG; Barr AM. (Frontiers in Psychiatry, 2022)

Assessment of Bioactivity-Modulating Pseudo-Ring Formation in Psilocin and Related Tryptamines. - Lenz C; Dörner S; Trottmann F; Hertweck C; Sherwood A; Hoffmeister D. (ChemBioChem, 2022)

Psilocybin-induced takotsubo cardiomyopathy. - Kotts WJ; Gamble DT; Dawson DK; Connor D. (BMJ Case Reports, 2022)

The Efficacy of Psilocybin in the Treatment of Depression andAnxiety: A Meta-Analysis - Andrew Hodge; Suporn Sukpraprut-Braaten; Robert Strayhan (Current Psychiatry Research and Reviews, 2022)

Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy. - Mocanu V; Mackay L; Christie D; Argento E. (Substance Abuse Treatment Prevention and Policy, 2022)

Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations. - Ortiz CE; Dourron HM; Sweat NW; Garcia-Romeu A; MacCarthy S; Anderson BT; Hendricks PS. (2022)

A critique of: Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds - Carhart-Harris R; Daws RE; Nutt D. (PsyArXiv, 2022)

A critique of: Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds (PsyArXiv, 2022)

Magic mushroom extracts in lipid membranes. - Nguyen TQT; Lund FW; Zanjani AAH; Khandelia H. (Biochimica et Biophysica Acta (BBA) - Biomembranes, 2022)

The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol. - Johansen L; Liknaitzky P; Nedeljkovic M; Mastin-Purcell L; Murray G (Systematic reviews, 2022)

Receptor binding profiles and behavioral effects of psilocybin analogs - Grant C. Glatfelter; David R. Manke; Andrew R. Chadayne; Michael H. Baumann (The FASEB Journal, 2022)

The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice. - Stein CA; Penn A; Van Hope S; Dorsen CG; Mangini M (Journal of midwifery & women's health, 2022)

Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy in Major Depression - University of Zurich (ClinicalTrials.gov, 2022)

Sex-Specific Effects of Psychedelic Drug Exposure on Central Amygdala Reactivity and Behavioral Responding - Effinger D; Quadir S; Ramage M; Cone M; Herman M. (bioRxiv, 2022)

P388. Open Label Psilocybin Administration in Severely Treatment Resistant Depression - Scott Aaronson; Tammy Miller; Samuel Rudow; MacKenzie Forbes; Trisha Suppes (Biological Psychiatry, 2022)

P450. Pilot Study Evaluation of Psilocybin Therapy for Anorexia Nervosa: Safety, Acceptability, and Preliminary Efficacy - Stéphanie Knatz Peck; Samatha Shao; Susan Murray; Walter H. Kaye (Biological Psychiatry, 2022)

Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds - Doss M; Barrett FS; Corlett PR. (PsyArXiv, 2022)

Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds (PsyArXiv, 2022)

Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges. - Rossi GN; Hallak JEC; Bouso Saiz JC; Dos Santos RG. (Expert Opinion on Drug Safety, 2022)

Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation. - Raut SB; Marathe PA; van Eijk L; Eri R; Ravindran M; Benedek DM; Ursano RJ; Canales JJ; Johnson LR. (2022)

The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies. - Gill H; Puramat P; Patel P; Gill B; Marks CA; Rodrigues NB; Castle D; Cha DS; Mansur RB; Rosenblat JD; McIntyre RS. (2022)

Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex. - Girn M; Roseman L; Bernhardt B; Smallwood J; Carhart-Harris R; Nathan Spreng R. (NeuroImage, 2022)

Will psilocybin lose its magic in the clinical setting? - Hayes C; Wahba M; Watson S. (2022)

Is PTSD an Evolutionary Survival Adaptation Initiated by Unrestrained Cytokine Signaling and Maintained by Epigenetic Change? - Rudzki S. (Military Medicine, 2022)

Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders. - Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W. (2022)

Increased global integration in the brain after psilocybin therapy for depression. - Daws RE; Timmermann C; Giribaldi B; Sexton JD; Wall MB; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R. (Nature Medicine, 2022)

Combining FTIR-ATR and OPLS-DA methods for magic mushrooms discrimination - Cátia Esteves; Elena M. M. de Redrojo; José Luis Manjón; Gabriel Moreno; Filipe E. Antunes; Gemma Montalvo; Fernando E. Ortega-Ojeda (Forensic Chemistry, 2022)

Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample. - Jones G; Ricard JA; Lipson J; Nock MK. (Scientific Reports, 2022)

Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. - Kopra EI; Ferris JA; Winstock AR; Young AH; Rucker JJ. (Journal of Psychopharmacology, 2022)

Production and extraction of psilocybin and psilocin from Psilocybe spp. mushrooms - Costa Fernandes Joana Margarida; Filho Cesar; Machado Brito-da-Costa Andreia; Marin-Bruzos Marieta; Saayman Jean; Sanders Daniel; Dinis-Oliveira Ricardo Jorge (RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia, 2022)

Evaluation of a quantitative analytical method for psilocin and psilocybin using HPLC-DAD - Filho Cesar; Costa Fernandes Joana Margarida; Machado Brito-da-Costa Andreia; Marin-Bruzos Marieta; Saayman Jean; Sanders Daniel; Dinis-Oliveira Ricardo Jorge (RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia, 2022)

Psylocybin and Psilocin as new tools to fight depression: an overview of the Pharmacodynamic and pharmacokinetic mechanisms - Lemos Martins Sofia; Machado Brito-da-Costa Andreia; Madureira-Carvalho Áurea; Dinis-Oliveira Ricardo Jorge; Dias da Silva Diana (RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia, 2022)

Psilocybe mexicana R. Heim - Mexikanischer Kahlkopf - Antonia Kuhn; Matthias F. Melzig (Zeitschrift für Phytotherapie, 2022)

Psilocybin increases brain network integration in patients with depression. (Nature Medicine, 2022)

Models of psychedelic drug action: modulation of cortical-subcortical circuits. - Doss MK; Madden MB; Gaddis A; Nebel MB; Griffiths RR; Mathur BN; Barrett FS. (Brain, 2022)

Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channel-Mediated Cardiotoxicity. - Hackl B; Todt H; Kubista H; Kubista H; Hilber K; Koenig X. (The International Journal of Neuropsychopharmacology, 2022)

Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression. - Murphy R; Kettner H; Zeifman R; Giribaldi B; Kartner L; Martell J; Read T; Murphy-Beiner A; Baker-Jones M; Nutt D; Erritzoe D; Watts R; et al. (Frontiers in Pharmacology, 2022)

Tentative identification of in vitro metabolites of O-acetylpsilocin (psilacetin, 4-AcO-DMT) by UHPLC-Q-Orbitrap MS. - Zhai W; Li L; Zhao J; Xiang P; Liu M; Shi Y; Dang Y. (Drug Testing and Analysis, 2022)

Psilocybin-Assisted Compassion Focused Therapy for Depression. - Pots W; Chakhssi F. (Frontiers in Psychology, 2022)

Race, Ethnic, and Sex Differences in Prevalence of and Trends in Hallucinogen Consumption Among Lifetime Users in the United States Between 2015 and 2019. - Davis AK; Arterberry BJ; Xin Y; Agin-Liebes G; Schwarting C; Williams MT. (Frontiers in Epidemiology, 2022)

How Important Is a Guide Who Has Taken Psilocybin in Psilocybin-Assisted Therapy for Depression? - Earleywine M; Low F; Altman BR; De Leo J. (Journal of Psychoactive Drugs, 2022)

Shared and distinct brain regions targeted for immediate early gene expression by ketamine and psilocybin - Davoudian PA; Shao L; Kwan AC. (bioRxiv, 2022)

The promises and perils of psychedelic pharmacology for psychiatry. - McClure-Begley TD; Roth BL. (2022)

Phenomenological assessment of psychedelics induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI). - Dworatzyk K; Jansen T; Schmidt TT. (PLoS ONE, 2022)

Development of an E. coli-based norbaeocystin production platform and evaluation of behavioral effects in rats. - Adams AM; Anas NA; Sen AK; Hinegardner-Hendricks JD; O'Dell PJ; Gibbons WJ; Flower JE; McMurray MS; Jones JA. (Metabolic Engineering Communications, 2022)

A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders. - Kisely S; Connor M; Somogyi AA; Siskind D. (2022)

Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain. - Meade E; Hehir S; Rowan N; Garvey M. (2022)

Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report. - McCulloch DE; Grzywacz MZ; Madsen MK; Jensen PS; Ozenne B; Armand S; Knudsen GM; Fisher PM; Stenbæk DS. (Frontiers in Pharmacology, 2022)

Psilocybin Combines Rapid Synaptogenic And Anti-Inflammatory Effects In Vitro - Smedfors G; Glotfelty E; Kalani N; Hjelle CP; Horntvedt O; Wellfelt K; Brodin A; von Kieseritzky F; Olson L; Karlsson T. (Research Square, 2022)

Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer. - Bates N; Bello JK; Osazuwa-Peters N; Sullivan MD; Scherrer JF. (2022)

Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - Rationale and study design. - Mertens LJ; Koslowski M; Betzler F; Evens R; Gilles M; Jungaberle A; Jungaberle H; Majić T; Ströhle A; Wolff M; Wellek S; Gründer G. (Neuroscience Applied, 2022)

Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. - Sarparast A; Thomas K; Malcolm B; Stauffer CS. (2022)

Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy. - Sekula AD; Downey L; Puspanathan P. (2022)

Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity - Gaddis A; Lidstone DE; Nebel MB; Griffiths R; Mostofsky SH; Mejia A; Barrett F. (bioRxiv, 2022)

Persisting decreases in state and trait anxiety post-psilocybin: A naturalistic, observational study among retreat attendees - Kiraga M; Kuypers KPC; Uthaug MV; Ramaekers J; Mason NL. (medRxiv, 2022)

The therapeutic potential of psilocybin: a systematic review. - van Amsterdam J; van den Brink W. (2022)

Effects of the 5-HT2A receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents. - Jaster AM; Elder H; Marsh SA; de la Fuente Revenga M; Negus SS; González-Maeso J. (2022)

Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats. - Popik P; Hogendorf A; Bugno R; Khoo SY; Zajdel P; Malikowska-Racia N; Nikiforuk A; Golebiowska J. (Psychopharmacology, 2022)

Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. - Schlag AK; Aday J; Salam I; Neill JC; Nutt DJ (Journal of psychopharmacology (Oxford, England), 2022)

The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs' effects on psychological flexibility. - Wolff M; Mertens LJ; Walter M; Enge S; Evens R. (Journal of Psychopharmacology, 2022)

The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review. - Hodge AT; Sukpraprut-Braaten S; Narlesky M; Strayhan RC. (2022)

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. - Holze F; Ley L; Müller F; Becker AM; Straumann I; Vizeli P; Kuehne SS; Roder MA; Duthaler U; Kolaczynska KE; Varghese N; Eckert A; et al. (Neuropsychopharmacology, 2022)

Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice. - Thomas CW; Blanco-Duque C; Bréant BJ; Goodwin GM; Sharp T; Bannerman DM; Vyazovskiy VV. (Translational Psychiatry, 2022)

Natural language signatures of psilocybin microdosing - Sanz C; Cavanna F; Muller S; de la Fuente L; Zamberlan F; Palmucci M; Janeckova L; Kuchar M; Carrillo F; García AM; Pallavicini C; Tagliazucchi E. (bioRxiv, 2022)

Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study. - Jones GM; Nock MK. (Scientific Reports, 2022)

Increased low-frequency brain responses to music after psilocybin therapy for depression - Wall MB; Lam C; Ertl N; Kaelen M; Roseman L; Nutt DJ; Carhart-Harris RL. (bioRxiv, 2022)

A Randomized Controlled Trial of the Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion - NYU Langone Health (ClinicalTrials.gov, 2022)

Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis. - Yu CL; Liang CS; Yang FC; Tu YK; Hsu CW; Carvalho AF; Stubbs B; Thompson T; Tsai CK; Yeh TC; Yang SN; Shin JI; et al. (2022)

Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development. - Van Court RC; Wiseman MS; Meyer KW; Ballhorn DJ; Amses KR; Slot JC; Dentinger BTM; Garibay-Orijel R; Uehling JK. (2022)

The Therapeutic Potential of Psychedelic-assisted Therapies for Symptom Control in Patients Diagnosed With Serious Illness: A Systematic Review. - Maia LO; Beaussant Y; Garcia ACM. (2022)

Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective? - Coppola M; Bevione F; Mondola R. (2022)

Psilocybin: Characterization of the Metastable Zone Width (MSZW), Control of Anhydrous Polymorphs, and Particle Size Distribution (PSD). - Kargbo RB; Sherwood AM; Meisenheimer P; Lenoch K; Abebe S. (ACS Omega, 2022)

Genomic Analysis of Stropharia rugosoannulata Reveals Its Nutritional Strategy and Application Potential in Bioremediation. - Yang Y; Meng G; Ni S; Zhang H; Dong C. (Journal of Fungi, 2022)

Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review. - Ziff S; Stern B; Lewis G; Majeed M; Gorantla VR. (2022)

Hallucinogen Use and Misuse in Older Adults. - Redden WM; Paracha SU; Sheheryar Q. (2022)

Crystallographic hallucinations. - Toby BH (Acta crystallographica. Section C, Structural chemistry, 2022)

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. - Gukasyan N; Davis AK; Barrett FS; Cosimano MP; Sepeda ND; Johnson MW; Griffiths RR. (Journal of Psychopharmacology, 2022)

Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine. - Averill LA; Abdallah CG (Expert opinion on investigational drugs, 2022)

[Are psychedelics fast acting antidepressant agents?] - Gründer G; Brand M; Kärtner L; Scharf D; Schmitz C; Spangemacher M; Mertens LJ. (2022)

Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder. - Markopoulos A; Inserra A; De Gregorio D; Gobbi G. (2022)

Structure-based discovery of nonhallucinogenic psychedelic analogs. - Cao D; Yu J; Wang H; Luo Z; Liu X; He L; Qi J; Fan L; Tang L; Chen Z; Li J; Cheng J; et al. (Science, 2022)

Comment and Response: (Lugo-Radillo & Cortez-Lopez, 2020) Long-Term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-Containing Mushrooms. - Fitzpatrick CM; Anderson BT; Agin-Liebes G; Guydish J. (2022)

Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants. - Müller F; Kraus E; Holze F; Becker A; Ley L; Schmid Y; Vizeli P; Liechti ME; Borgwardt S. (Psychopharmacology, 2022)

Psychedelic-assisted psychotherapy for the treatment of major depression: a synthesis of phenomenological explanations. - Miceli McMillan R; Jordens C. (2022)

Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation. - Barrett FS; Zhou Y; Carbonaro TM; Roberts JM; Smith GS; Griffiths RR; Wong DF. (Frontiers in Neuroergonomics, 2022)

Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry. - Sakurai H; Yonezawa K; Tani H; Mimura M; Bauer M; Uchida H. (2022)

Psilocybine vergeleken met escitalopram bij depressie - Jurriaan F. M. Strous (Pure Amsterdam UMC, 2022)

[Psilocybin compared with escitalopram for depression]. - Strous JFM. (PubMed, 2022)

Analysis of recreational psychedelic substance use experiences classified by substance. - Hase A; Erdmann M; Limbach V; Hasler G. (Psychopharmacology, 2022)

In Silico Studies on Psilocybin Drug Derivatives Against SARS-CoV-2 and Cytokine Storm of Human Interleukin-6 Receptor. - Khan FI; Hassan F; Lai D. (Frontiers in Immunology, 2022)

Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. - Bender D; Hellerstein DJ. (2022)

Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia. - Glynos NG; Pierce J; Davis AK; McAfee J; Boehnke KF. (Journal of Psychoactive Drugs, 2022)

MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. - Jones GM; Nock MK. (Journal of Psychopharmacology, 2022)

Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. - Jones GM; Nock MK. (Journal of Psychopharmacology, 2022)

The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. - Rucker JJ; Marwood L; Ajantaival RJ; Bird C; Eriksson H; Harrison J; Lennard-Jones M; Mistry S; Saldarini F; Stansfield S; Tai SJ; Williams S; et al. (Journal of Psychopharmacology, 2022)

Exploring the Credibility of Psilocybin-assisted Therapy and Cognitive-behavioral Therapy for Depression. - Altman BR; Earleywine M; De Leo J. (Journal of Psychoactive Drugs, 2022)

Acute psilocybin and ketanserin effects on cerebral blood flow: 5-HT2AR neuromodulatory effects in healthy humans - Klaus Richter Larsen; Drummond E-Wen McCulloch; Brice Ozenne; Ulrich Lindberg; Sophia Armand; M. Madsen; Dea Siggaard Stenbæk; Gitte M. Knudsen; Patrick M. Fisher (Neuroscience Applied, 2021)